Coinciding with the 50th anniversary of cancer research at MIT, a feature story tracing Alnylam’s success in developing RNAi therapies perfectly encapsulates the transformational impact and disciplinary diversity that characterize our community. Incorporating contributions from the Sharp and Langer Labs, with their alumni and colleagues, Alnylam has several medicines approved by the FDA and a rapidly expanding clinical pipeline.